254 related articles for article (PubMed ID: 16705043)
1. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
Jois RN; Leeder J; Gibb A; Gaffney K; Macgregor A; Somerville M; Scott DG
Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
[TBL] [Abstract][Full Text] [Related]
2. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
3. Infliximab treatment in ankylosing spondylitis: an observational study.
Nikas SN; Alamanos Y; Voulgari PV; Pliakou XI; Papadopoulos CG; Drosos AA
Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
5. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
[TBL] [Abstract][Full Text] [Related]
7. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
Cheung PP; Tymms KE; Wilson BJ; Shadbolt B; Brook AS; Dorai Raj AK; Khoo KB
Intern Med J; 2008 Jun; 38(6):396-401. PubMed ID: 18336538
[TBL] [Abstract][Full Text] [Related]
8. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
Keeling S; Oswald A; Russell AS; Maksymowych WP
J Rheumatol; 2006 Mar; 33(3):558-61. PubMed ID: 16463437
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
Inman RD; Maksymowych WP;
J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
[TBL] [Abstract][Full Text] [Related]
10. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
11. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
[TBL] [Abstract][Full Text] [Related]
12. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study.
Collantes-Estevez E; Muñoz-Villanueva MC; Zarco P; Torre-Alonso JC; Gratacós J; González C; Sanmartí R; Cañete JD;
Rheumatology (Oxford); 2005 Dec; 44(12):1555-8. PubMed ID: 16118228
[TBL] [Abstract][Full Text] [Related]
14. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2005 Feb; 64(2):229-34. PubMed ID: 15388511
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
[TBL] [Abstract][Full Text] [Related]
16. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
17. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J
Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
[TBL] [Abstract][Full Text] [Related]
19. [Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis].
Vinagre F; Santos MJ; Silva JC
Acta Reumatol Port; 2007; 32(3):271-3. PubMed ID: 17940497
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial.
Fautrel B; Benhamou M; Breban M; Roy C; Lenoir C; Trape G; Baleydier A; Ravaud P; Dougados M
Ann Rheum Dis; 2010 Feb; 69(2):424-7. PubMed ID: 19740900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
